product name Bilobalide
Description: Bilobalide (BB) is a biologically active terpenic trilactone isolated from Ginkgo biloba (GB). A number of studies have demonstrated its neuroprotective effects, for instance: in vitro experiments showed that inhibition by BB and GB was abolished in mutant receptors containing T6S and S12A substitutions, but their potencies were enhanced (42- and 125-fold, respectively) in S2A mutant receptors. BB enhanced the secretion of α-secretase-cleaved soluble amyloid precursor protein (sAPPα, a by-product of non-amyloidogenic processing of APP) and decreased the β amyloid protein (Aβ, a by-product of amyloidogenic processing of APP) via PI3K-dependent pathway.
References: Apoptosis. 2010 Jun;15(6):715-27; J Pharm Pharmacol. 2007 Jun;59(6):871-7.
326.3
Formula
C15H18O8
CAS No.
33570-04-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: > 10 mM
Water:
Ethanol:
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Inhibition by BB and GB was abolished in mutant receptors containing T6S and S12A substitutions, but their potencies were enhanced (42- and 125-fold, respectively) in S2A mutant receptors. BB enhanced the secretion of α-secretase-cleaved soluble amyloid precursor protein (sAPPα, a by-product of non-amyloidogenic processing of APP) and decreased the β amyloid protein (Aβ, a by-product of amyloidogenic processing of APP) via PI3K-dependent pathway. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Oral administration of bilobalide (10-30 mg/kg) significantly inhibited thermal hyperalgesia in response to carrageenan, capsaicin and paw incision, independent of dose, with an efficacy similar to that of diclofenac. In the carrageenan model, mechanical hypersensitivity and paw oedema were also significantly reduced after treatment with bilobalide (10-30 mg/kg). BB(4 and 8 mg/kg) significantly protected VD rats against cognitive deficits in the Morris water maze. Biochemical assessment showed that BB (4 and 8 mg/kg) increased superoxide dismutase (SOD) activity and glutathione (GSH) content, and decreased nitric oxide synthase (NOS) activity and malondialdehyde (MDA) content. |
| Animal model | |
| Formulation & Dosage | |
| References | Apoptosis. 15: 715-727, 2010; J. Pharm. Pharmacol. 59: 871-877, 2007. |
